This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned on this page and/or subsequent pages.
Prescribing information links can be found at the bottom of the page.
Cardio-metabolic resources
Dermatology resources
Haematology resources
Immunology resources
Neuroscience resources
Oncology resources
Radioligand therapy (RLT) resources
Respiratory and inflammation resources
Rheumatology resources
AIMOVIG® (erenumab) Prescribing information (external link)
COSENTYX® (secukinumab) Prescribing information (external link)
ENTRESTO® (sacubitril/valsartan) Prescribing information (external link)
FABHALTA®▼ (iptacopan) Prescribing information (external link)
ILARIS® (canakinumab) Prescribing information (external link)
JAKAVI® (ruxolitinib) Prescribing information (external link)
KESIMPTA®▼ (ofatumumab) Prescribing information (external link)
KISQALI® (ribociclib) Prescribing information (external link)
LEQVIO® (inclisiran) Prescribing information (external link)
MAYZENT® (siponimod) Prescribing information (external link)
SANDOSTATIN® LAR® (octreotide acetate) Prescribing information (external link)
SCEMBLIX®▼ (asciminib) Prescribing information (external link)
XOLAIR® (omalizumab) Prescribing information (external link)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
